Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96RT7
UPID:
GCP6_HUMAN
Alternative names:
-
Alternative UPACC:
Q96RT7; Q5JZ80; Q6PJ40; Q86YE9; Q9BY91; Q9UGX3; Q9UGX4
Background:
Gamma-tubulin complex component 6 plays a pivotal role in cellular processes by being essential for microtubule nucleation at the centrosome. This protein is integral to the formation and stabilization of microtubules, which are critical for cell shape, intracellular transport, and cell division.
Therapeutic significance:
Linked to Microcephaly and chorioretinopathy, autosomal recessive, 1, Gamma-tubulin complex component 6's understanding could pave the way for innovative treatments. This condition, marked by microcephaly, cognitive impairment, and visual impairment, underscores the protein's potential in therapeutic strategies.